Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Astellas Researcher And U.S. Team Find Drug Target For Schizophrenia 

This article was originally published in PharmAsia News

Executive Summary

Chief Researcher Mitsuyuki Matsumoto of Tokyo-based Astellas Pharma and a research team from the U.S. National Institutes of Mental Health found a protein that leads to the onset of schizophrenia symptoms including loss of memory and movement disorder. The protein SERB2 was discovered through pharmaceutical research on human and animal genomes. Recent testing on mice found that a genetically modified mouse with surplus amounts of SREB2 was found to develop a lighter weight brain, slower movement and lower information processing ability. NIMH team analyzed DNA samples of schizophrenia patients and further confirmed the role of SREB2 as the disease susceptibility gene. (Click here for more - Japanese language

You may also be interested in...

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts